

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (Currently Amended): A method of compensating for an absolute or relative testosterone deficiency in a patient who has said testosterone deficiency with simultaneous prophylaxis in said patient for the development of a benign prostatic hyperplasia or a prostate cancer comprising administering to said patient a combination of an androgenically effective amount of a natural or synthetic androgen, and a gestagenically effective amount of a gestagen, an antigestagen, an antiestrogen, a GnRH analog, a testosterone-5 α -reductase inhibitor, an α -andreno-receptor blocker or a phosphodiesterase inhibitor.

Claim 2 (Previously Presented): A method according to claim 1, wherein the natural androgen component is testosterone, testosterone undecanoate, dehydroepiandrosterone, dehydroepiandrosterone sulfate, testosterone propionate, testosterone enanthate, testosterone buciclate, testosterone cypionate or androstene dione.

Claim 3 (Previously Presented): A method according to claim 1, wherein the synthetic androgen component is 17-methyltestosterone, fluoxymesterone, danazol, mesterolone, nandrolone decanoate, nandrolone phenylpropionate, oxandrolone, oxymetholone, or stanazolol.

Claim 4 (Previously Presented): A method according to claim 1, wherein the gestagen component is dienogest, levonorgestrel, gestodene, desogestrel, norgestimate, norethisterone, a norethisterone ester, levonorgestrel, progesterone, chloromadinone acetate, cyproterone acetate, medroxy progesterone acetate, megestrol acetate, dydrogesterone, trimegestone or nomegestrol.

Claim 5 (Withdrawn) A method according to claim 1, wherein the antigestagen component is 4-[17 β -Hydroxy-17 α -(methoxymethyl)-3oxoestra-4,9-dien-11 β -yl]benzaldehyde-1(E)-oxime (J 912);

4-[-17 β -methoxy-17 α -(methoxymethyl)-3-oxo-estra-4,9-dien-11 β -yl]-benzaldehyde-1(E)-
{O-[(ethylthio)carbonyl]}-oxime (J 1042);

4-[9 α ,10 α -epoxy-17 β -hydroxy-17 α -(methoxymethyl)-3-oxo-estr-4-en-11 β -yl]-
benzaldehyde-1(E)-oxime (J 1116);

4-[17 β -methoxy-17 α -(methoxymethyl)-3oxoestra-4,9-dien-11 β -yl]benzaldehyde-1(E)-
oxime (J 867);

4-[17 β -hydroxy-17 α -(methoxymethyl)-3oxoestra-4,9-dien-11 β -yl]benzaldehyde-1(E)-{O-
[(N-ethyl)-carbonyl]}-oxime (J 956);

11 β -[(4-N,N-dimethylamino)-phenyl]-17 β -hydroxy-17 α -propinyl-estra-4,9-dien-3-one
(RU 38 486 - mifepristone);

11 β -[(4-N,N-dimethylamino)-phenyl]-17 α -hydroxy-17 β -(3-hydroxypropyl)-13 α -methyl-
gona-4,9-dien-3-one (ZK 98299 - onapristone);

11 β -(4-acetylphenyl)-17 β -hydroxy-17 α -propinyl-estra-4,9-dien-3-one (ZK 112993);

11 β -[(4-N,N-dimethylamino)-phenyl]-17 β -hydroxy-17 α -(3-hydroxy-1-(Z)-propenyl)-
estra-4,9-dien-3-one (ZK 98 734 - lilopristone);

11 β -[(4-N,N-dimethylamino)-phenyl]-17 β -hydroxy-17 α -(3-hydroxy-1-(Z)-propenyl)-
estra-4-en-3-one (ZK 137 316);

11 β -[(4-N,N-dimethylamino)-phenyl]-6 β -methyl-4',5'dihydrospiro-[estra-4,9-diene-
17,2'(3'H)-furan]-3-one (ORG 31 710);

11 β -[(4-N,N-dimethylamino)-phenyl]-7 β -methyl-4',5'dihydrospiro-[estra-4,9-diene-
17,2'(3'H)-furan]-3-one (ORG 31 806); or

11 β -(4-acetylphenyl)-(3'E)-ethylidene-4',5'dihydrospiro-[estra-4,9-diene-17,2'(3H)-furan]-
3-one (ORG 33 628).

Claim 6 (cancelled)

Claim 7 (Withdrawn): A method according to claim 1, wherein the GnRH-analog component is
buserelin, goserelin, nafarelin, triptorelin or deslorelin, leuprolide or leuprolide acetate.

Claim 8 (Withdrawn): A method according to claim 1, wherein the antiestrogen component is tamoxifen, raloxifene, panomifene, toremifene, iproxifene or idoxifene.

Claim 9 (Withdrawn): A method according to claim 1, wherein the testosterone-5 α -reductase-inhibitor component is finasteride, epristeride, permixon, or turosteride.

Claim 10 (Withdrawn): A method according to claim 1, wherein the α -andreno-receptor-blocker component is tolazoline, phentolamine, phenoxybenzamine, alfuzosin, or prazosin.

Claim 11 (Withdrawn): A method according to claim 1, wherein the phosphodiesterase-inhibitor component is amrinone, milrinone, trapidil, papaverine, vesnarinone or sildenafil.

Claim 12 (Previously Presented): A method of claim 1 wherein said combination is used in the form of a tablet, capsule, coated tablet, transdermal therapy system, ampoule, suppository, gel, ointment, nose drop, implant, pressed part or biodegradable microspheres.

Claim 13 (Previously Presented): A method according to claim 2, wherein a gestagen is administered which is dienogest, levonorgestrel, gestodene, desogestrel, norgestimate, norethisterone, norethisterone acetate, levonorgestrel or progesterone, chloromadinone acetate, cyproterone acetate, medroxy progesterone acetate, megestrol acetate, dydrogesterone, trimegestone or nomegestrol.

Claim 14 (Previously Presented): A method according to claim 3, wherein a gestagen is administered which is dienogest, levonorgestrel, gestodene, desogestrel, norgestimate, norethisterone, norethisterone acetate, levonorgestrel or progesterone, chloromadinone acetate, cyproterone acetate, medroxy progesterone acetate, megestrol acetate, dydrogesterone, trimegestone or nomegestrol.

Claim 15 (Previously Presented): A method of claim 4 wherein the dosage of androgen is 250-1500 mg i.m. every 4 to 14 weeks and the dosage of gestagen is

20 µg to 20 mg.

Claim 16 (Previously Presented): A method of claim 13 wherein the dosage of androgen is 250-1500 mg i.m. every 4 to 14 weeks and the dosage of gestagen is 20 µg to 20 mg.

Claim 17 (Previously Presented): A method of claim 14 wherein the dosage of androgen is 250-1500 mg i.m. every 4 to 14 weeks and the dosage of gestagen is 20 µg to 20 mg.

Claim 18 (Withdrawn): A method according to claim 1, wherein said natural androgen is testosterone undecanoate.

Claim 19 (Withdrawn): A method according to claim 1, wherein said natural androgen is testosterone enanthate.

Claim 20 (Currently Amended): ~~A method according to claim 1, wherein a gestagen is administered which is dienogest~~ A method of compensating for an absolute or relative testosterone deficiency in a patient who has said testosterone deficiency with simultaneous prophylaxis in said patient for the development of a benign prostatic hyperplasia or a prostate cancer comprising administering to said patient a combination of a natural or synthetic androgen, and dienogest, an antigestagen, an antiestrogen, a GnRH analog, a testosterone-5 α -reductase inhibitor, an α -andreno-receptor blocker or a phosphodiesterase inhibitor.

Claim 21 (Withdrawn): A method according to claim 1, wherein a gestagen is administered which is a norethisterone ester.

Claim 22 (Withdrawn): A method according to claim 1, wherein a gestagen is administered which is chloromadinone.

Claim 23 (Withdrawn): A method according to claim 1, wherein a gestagen is administered which is cyproterone acetate.

Claim 24 (Withdrawn): A method according to claim 1, wherein an antigestagen is administered which is 4-[17 β -Hydroxy-17 α -(methoxymethyl)-3oxoestra-4,9-dien-11 β -yl]benzaldehyde-1(E)-oxime.

Claim 25 (Withdrawn): A method according to claim 1, wherein an antigestagen is administered which is 4-[-17 β -methoxy-17 α -(methoxymethyl)-3-oxo-estra-4,9-dien-11 β -yl]-benzaldehyde-1(E)-{O-[(ethylthio)carbonyl]}-oxime.

Claim 26 (Withdrawn): A method according to claim 1, wherein an antigestagen is administered which is 4-[9 α ,10 α -epoxy-17 β -hydroxy-17 α -(methoxymethyl)-3-oxo-estr-4-en-11 β -yl]-benzaldehyde-1(E)-oxime.

Claim 27 (Withdrawn): A method according to claim 1, wherein an antigestagen is administered which is 4-[17 β -methoxy-17 α -(methoxymethyl)-3oxoestra-4,9-dien-11 β -yl]benzaldehyde-1(E)-oxime.

Claim 28 (Withdrawn): A method according to claim 1, wherein an antigestagen is administered which is 4-[17 β -hydroxy-17 α -(methoxymethyl)-3oxoestra-4,9-dien-11 β -yl]benzaldehyde-1(E)-{O-[(N-ethyl)-carbonyl]}-oxime.

Claim 29. (New): A method according to claim 1, wherein the gestagen is administered in the form of a tablet or as an intranasal or rectal preparation form or as an implant or transdermally.

Claim 30 (New): A method of compensating for an absolute or relative testosterone deficiency in a patient who has said testosterone deficiency with simultaneous prophylaxis in said patient for the development of a benign prostatic hyperplasia comprising administering to said patient a combination of an androgenically effective amount of a natural or

synthetic androgen, and a gestagenically effective amount of a gestagen, an antigestagen, an antiestrogen, a GnRH analog, a testosterone-5 α -reductase inhibitor, an α -andreno-receptor blocker or a phosphodiesterase inhibitor.

Claim 31 (New): A method of compensating for an absolute or relative testosterone deficiency in a patient who has said testosterone deficiency with simultaneous prophylaxis in said patient for the development of a prostate cancer comprising administering to said patient a combination of an androgenically effective amount of a natural or synthetic androgen, and a gestagenically effective amount of a gestagen, an antigestagen, an antiestrogen, a GnRH analog, a testosterone-5 α -reductase inhibitor, an α -andreno-receptor blocker or a phosphodiesterase inhibitor.